一、中文名称：罗米司亭Nplate(Romiplostim) Anti Romiplostim Antibody ,Romiplostim Protein蛋白，抗体，试剂盒
二、产品描述
Romiplostim是一种血小板生成刺激二聚体Fc肽融合蛋白（肽体），通过激活血小板生成素受体来增加血小板生成。肽体分子有两个相同的单链亚基，每个亚基由269个氨基酸残基组成。每个亚基由一个IgG1 Fc载体结构域组成，该结构域共价连接到多肽序列，该多肽序列包含两个与血小板生成素受体c-Mpl相互作用的结合结构域。每个结构域由14个氨基酸组成。罗米司亭的氨基酸序列与内源性血小板生成素的氨基酸序列不同。Romiplostim 是通过大肠杆菌中的重组DNA技术生产的。作用机制：Romiplostim是一种血小板生成素受体激动剂，可通过c-Mpl激活细胞内转录途径以增加血小板的产生。它的作用也类似于血小板生成素（TPO），TPO是一种调节骨髓中血小板产生的内源性糖蛋白激素。
三、相关产品
Anti-Romiplostim (Nplate) ELISA Kit (KAD76501)
Mouse Anti-Romiplostim Polyclonal Antibody (PHE26003)
Anti-Romiplostim Monoclonal Antibody (1A430) (MHE26001)
Anti-Romiplostim Monoclonal Antibody (1A431) (MHE26002)
Anti-Romiplostim Monoclonal Antibody (1A432) (MHE26003)
Anti-Romiplostim Polyclonal Antibody (PHE26002)
Recombinant Romiplostim Protein, N-Fc (EHE26002)
Anti-Romiplostim (Nplate) ELISA Kit（KAD76501）
三、产品详情
名称：Mouse Anti-Romiplostim Polyclonal Antibody (PHE26003)
别名：Romiplate, Romiplostim, Nplate
货号：PHE26003
种属反应性：Human
宿主：Mouse
同种型：IgG
克隆类型：Polyclonal
免疫原：Romiplostim
经测试应用：ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
靶标：Thrombopoietin, C-mpl ligand, ML, Megakaryocyte colony-stimulating factor, Megakaryocyte growth and development factor, MGDF, Myeloproliferative leukemia virus oncogene ligand, THPO, MGDF
纯化方式：Purified by antigen affinity column.
Accession号：P40225
应用：ELISA, WB
状态：Liquid
保存溶液：0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
稳定性和存储：Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. (PHE26003)
四、参考文献：
Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia. PMID: 31545663
A Review of Romiplostim Mechanism of Action and Clinical Applicability. PMID: 34079225
Romiplostim. PMID: 18974747
A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. PMID: 32499239
Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia. PMID: 33249935
Efficacy and safety of romiplostim in refractory aplastic anaemia: a Phase II/III, multicentre, open-label study. PMID: 33152120
Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study. PMID: 35179784
Romiplostim: a review of its use in immune thrombocytopenia. PMID: 22316355
Romiplostim in children with newly diagnosed or persistent primary immune thrombocytopenia. PMID: 34308495
Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice. PMID: 31239245
Romiplostim: a novel thrombopoiesis-stimulating agent. PMID: 19386944
Efficacy and quality of life of Romiplostim in adults and children with immune thrombocytopenia: A review. PMID: 36550870
Romiplostim use in pregnant women with immune thrombocytopenia. PMID: 36156812
Romiplostim in chronic immune thrombocytopenic purpura. PMID: 19843480
Romiplostim management of immune thrombocytopenic purpura. PMID: 19401474
Romiplostim drug presence in pregnancy and lactation. PMID: 36848631
Development of Romiplostim for Treatment of Primary Immune Thrombocytopenia From a Pharmacokinetic and Pharmacodynamic Perspective. PMID: 27056734
Romiplostim and eltrombopag for immune thrombocytopenia: methods for indirect comparison. PMID: 22980701
Romiplostim: a breakthrough treatment for the management of immune thrombocytopenic purpura. PMID: 19200304
Thrombopoietin receptor agonists: ten years later. PMID: 31073079
Experts' review: the emerging roles of romiplostim in immune thrombocytopenia (ITP). PMID: 34313512
Use of Romiplostim during pregnancy as a rescue therapy in primary immune thrombocytopenia: Literature review and case description. PMID: 31116059
Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a single technology appraisal. PMID: 19804691
Development of romiplostim: a novel engineered peptibody. PMID: 25578414
Romiplostim for SARS-CoV-2 Vaccine Induced Immune Thrombocytopenia. PMID: 34757966
Romiplostim: a second-generation thrombopoietin agonist. PMID: 19436840
Romiplostim for the management of perioperative thrombocytopenia. PMID: 29767837
Immune Thrombocytopenia in a Kidney Transplant Recipient Treated with Romiplostim. PMID: 35033295
Romiplostim-induced myelofibrosis. PMID: 24175353
Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia. PMID: 33781612
Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura. PMID: 30880797
Romiplostim for PARP inhibitor-induced thrombocytopenia in solid tumor malignancies. PMID: 36050822
Safety of romiplostim administered immediately after cord-blood transplantation: a phase 1 trial. PMID: 37589942
The development of romiplostim for patients with immune thrombocytopenia. PMID: 21434943
A Review on Romiplostim Mechanism of Action and the Expressive Approach in E. coli. PMID: 38282441
Immunomodulation with romiplostim as a second-line strategy in primary immune thrombocytopenia: The iROM study. PMID: 37735543
Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma: The PLATUM trial. PMID: 31586022
Romiplostim in aplastic anaemia - another tool in the armamentarium. PMID: 33152102
Eltrombopag versus romiplostim in treatment of children with persistent or chronic immune thrombocytopenia: a systematic review incorporating an indirect-comparison meta-analysis. PMID: 29330464
Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists. PMID: 34160821
Immunomodulation in Primary Immune Thrombocytopenia: A Possible Role of the Fc Fragment of Romiplostim? PMID: 31214173
Spotlight on romiplostim in the treatment of children with chronic immune thrombocytopenia: design, development, and potential place in therapy. PMID: 28408804
Safety of romiplostim and eltrombopag for children with immune thrombocytopenia: a pharmacovigilance study of the FDA adverse event reporting system database. PMID: 36803342
Romiplostim for Primary Immune Thrombocytopenia in Routine Clinical Practice: Results from a Multicentre Observational Study in Germany. PMID: 34959233
An update on romiplostim for treatment of acute radiation syndrome. PMID: 35274632
Romiplostim-related myelofibrosis in refractory primary immune thrombocytopenia: A Case report. PMID: 31232923
Romiplostim (Nplate()) as an effective radiation countermeasure to improve survival and platelet recovery in mice. PMID: 31021662
Comparability of biosimilar romiplostim with originator: Protein characterization, animal pharmacodynamics and pharmacokinetics. PMID: 36871442
Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside. PMID: 20298251
Successful treatment of refractory secondary immune thrombocytopenia (antiphospholipid antibody syndrome-associated) with the combination of rituximab and romiplostim at the cost of severe bone pain: A case report and review of literature. PMID: 32611269
Romiplostim as Adjunctive Treatment of Refractory Amegakaryocytic Immune Thrombocytopenia in a Dog. PMID: 33115689
Romiplostim for thrombocytopenia following allogeneic stem cell transplantation: A case series. PMID: 30030975
Romiplostim use for thrombocytopenia following allogeneic hematopoietic stem cell transplantation: a case series from a single center in Qatar. PMID: 37961987
Assessment of romiplostim immunogenicity in pediatric patients in clinical trials and in a global postmarketing registry. PMID: 34638135
Romiplostim treatment for children with immune thrombocytopenia: Results of an integrated database of five clinical trials. PMID: 32902132
Romiplostim in the management of the thrombocytopenic surgical patient. PMID: 26033367
Romiplostim for Immune Thrombocytopenia in Neuroblastoma Patients Receiving Chemotherapy. PMID: 29683946
Efficacy of romiplostim in treatment of thrombocytopenia in children with Wiskott-Aldrich syndrome. PMID: 33131064
Romiplostim for management of chemotherapy-induced thrombocytopenia. PMID: 24414994
Romiplostim for therapy-related thrombocytopenia in pediatric malignancies. PMID: 28150377
A Novel Use of Romiplostim for SARS-CoV-2-induced Thrombocytopenia. PMID: 33003146
Generic romiplostim for children with persistent or chronic immune thrombocytopenia: Experience from a tertiary care centre in North India. PMID: 35467751
Romiplostim is effective for eltrombopag-refractory aplastic anemia: results of a retrospective study. PMID: 32876852
Romiplostim dose-response in patients with myelodysplastic syndromes. PMID: 23171070
The burden of immune thrombocytopenia in adults: evaluation of the thrombopoietin receptor agonist romiplostim. PMID: 22533524
Romiplostim promotes platelet recovery in a mouse model of multicycle chemotherapy-induced thrombocytopenia. PMID: 25754671
Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. PMID: 27103127
Romiplostim as early treatment for refractory primary immune thrombocytopenia. PMID: 24068656
详情请咨询Antibodysystem中国授权总代理-武汉佰乐博生物技术有限公司
网址：https://www.antibodysystem.com/product/21592.html
武汉佰乐博生物技术有限公司作为法国Antibodysystem品牌亚洲区授权总代理。提供近3万种蛋白、抗体等核心生命科学试剂，旨在为生命科学科研工作者提供专业、全面、可靠的试剂产品。
试剂 | 耗材 | 定制 | 实验服务 | 供应链
免费热线：027-65279366 /18108604356
